High Density Lipoproteins in Health and in Disease

The Expert Panel . Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, eval-uation, and treatment of high blood cholesterol in adults (adult treatment panel II). J Am Med Inform Assoc. 1993;269:3015–23.

Hokanson JE , Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cho-lesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213–9.

Castelli WP , Garrison RJ , Wilson PW , Abbott RD , Kalousdian S , Kannel WB. Incidence of coronary heart disease and lipoprotein choles-terol levels: The Framingham Study. JAMA. 1986;256:2835–8.

Havel RJ , Kane JP. Structure and metabolism of plasma lipopro-teins. In: Scriver CR , Beaudet AL , Sly WS and Valle D , eds. The metabolic and molecular basis of inherited disease, 7th edition. McGraw-Hill, USA. 1995;1841–51.

Eisenberg S. High density lipoprotein metabolism. J Lipid Res. 1984;25:1017–58.

Tuajuanda C , Jordan-Starck J-S , White DP , Aronow BJ , Harmony JAK . Apolipoprotein J: a membrane policeman? Curr Opin Lipidol. 1992;3:75–85.

Kounnas MZ , Loukinova EB , Stefansson S , Harmony JA , Brewer BH , Strickland KD , Argraves WS. Identification of glycoprotein 330 as an endocytic receptor for apolipoprotein J/clusterin. J Biol Chem. 1995;270:13070–5.

Serrato M , Marian AJ. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coro-nary artery disease. J Clin Invest. 1995;96:3005–8.

Takahashi Y , Chiba H , Matsuno K , Akita H , Hui SP , Nagasaka H , Nakamura H , Kobayashi K , Tandon NN , Jamieson GA. Native lipopro-teins inhibit platelet activation induced by oxidized lipoproteins. Biochem Biophys Res Comm. 1996;222:453–9.

Acton S , Rigotti A , Landschulz KT , Xu S , Hobbs HH , Krieger M. Identification of scavenger receptor SR-BI as a high density lipopro-tein receptor. Science. 1996;271:518–21.

Smith AB , Hajduck SL. Identification of haptoglobin as a natural inhibitor of trypanocidal activity in human serum. Proc Natl Acad Sci USA. 1995;92:10262–6.

Smith AB , Esko JD , Hajduk SL. Killing of trypanosomes by the human haptoglobin-related protein. Science. 1995;268:284–6.

Cockerill GW , Rye K-A , Gamble JR , Vadas MA , Barter PJ. HDL inhibit cytokine-induced expression of endothelial cell adhesion moleculae. Arterioscler Thromb Vasc Biol. 1995;15:1987–94.

Vinals M , Martinez-Gonzalez J , Badimon JJ , Badimon L. HDL-induced prostacyclin release in smooth muscle cells in dependent on cyclooxygenase-2 (Cox-2). Arterioscler Thromb Vasc Biol. 1997;17:3481–8.

Schaefer EJ , Lamon-Fava S , Ordovas JM , Cohn SD , Schaefer MM , Castelli WP , Wilson PWG . Factors associated with low and elevat-ed plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. J Lipid Res. 1994;35:871–82.

Gordon T , Castelli WP , Hjortland MC , Kannel WB , Dawbwr TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62:707–14.

Gordon T , Kannel WB , Castelli WP , Dawber TR. Lipoproteins, cardiovascular disease, and death. The Framingham Study. Arch Intern Med. 1981;141:1128–31.

Bass KM , Newschaffer CJ , Klag MJ , Bush TL. Plasma lipopro-tein levels as predictors of cardiovascular death in women. Arch Intern Med. 1993;153:2209–16.

Assmann G , Schulte H , von Eckardstein A , Huang Y. High-den-sity lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis. 1996;124:S11–20.

Stokes J III , Kannel WB , Wolf PA , Copples A , D'Agostino RB. The relative importance of selected risk factors for various manifesta-tions of cardiovascular disease among men and women from 35 to 64 years old: 30 years follow-up in the Framingham Study. Circulation. 1987;75:65–73.

Kannel WB. High-density lipoproteins: epidemiologic profile and risks of. coronary artery disease. Am J Cardiol. 1983;52:9B–12B.

Goldbourt U , Medalie JH. High-density lipoprotein cholesterol and incidence of coronary heart disease: the Israeli Ischemic Heart Disease Study. Am J Epidemiol. 1979;109:296–308.

Genest J Jr , McNamara JR , Ordovas JM , Jenner JL , Silberman SR , Anderson KM , Wilson PWF , Salem DN , Schaefer EJ. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein(a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol. 1992;19:792–802.

Barter PJ , Rye K-A . High density lipoproteins and coronary heart disease. Atherosclerosis. 1995;121:1–12.

Gaziano JM , Henneckens CH , O'Donnell CJ , Breslow JL. Fasting triglycerides, high density lipoprotein, and risk of myocardial infarction. Circulation. 1997;96:2520–5.

Weber M , McNicoll S , Lussier-Cacan S , Marcil M , Connelly P , Rondeau C , Latour Y , Connelly P , Davignon J , Genest J Jr . Plasma lipoproteins, apolipoprotein B, apolipoprotein E phenotypes and meta-bolic factors in premature CAD in French Canadians. Can J Cardiol. 1997;13:253–60.

Assmann G. The role of triglycerides in coronary artery disease: lessons from the Prsopective Cardiovascular Study in Munster. Am J Cardiol. 1992;79:10H–13H.

Laakso M , Lehto S , Penttilä I , Pyörälä K. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation. 1993;88:1421–30.

Stampfer MJ , Sacks FM , Salvini S , Willett WC , Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. New Eng J Med. 1991;325:373–81.

Cholesterol Lowering in the Patient with Coronary artery Disease. National Institutes of Health, National Heart, Lung and Blood Institute; National Cholesterol Education Program Adult Treatment Panel 2. (NIH Publ. 97-3794).

The Lipid Research Clinics Population Studies Data Book. Vol. 1. The prevalence study. Washington, D.C.: Department of Health and Human Services, Public Health Service, (NIH Publ. 80-1527).

Austin MA. Genetic epidemiology of LDL subclass phenotypes. Ann Med. 1992;24:472–81.

Frohlich J , Fodor G , McPherson R , Genest J , Langer N. For the Health Canada Working Party on the diagnosis and treatment of hyperc-holesterolemia and other dyslipidemias. Rationale for and outline of new Canadian guidelines. (Submitted).

Genest J Jr , McNamara JR , Salem DN , Cohn SD , Millar JS , Wilson PFW , Schaefer EJ. Prevalence of risk factors in men with prema-ture coronary artery disease. Am J Cardiol. 1991;67:1185–9.

Genest J Jr , Bard JM , Fruchart JC , Ordovas JM , Schaefer EJ. Familial Hypoalphalipoproteinemia in Premature Coronary Artery Disease. Arterioscler Thromb Vasc Biol. 1993;13:1728–37.

Karathanasis SK. Lipoprotein metabolism: high density lipopro-teins. In: Lusis AJ , Rotter RS , Sparkes RS , eds. Molecular genetics of coronary artery disease. Candidate genes and processes in atherosclerosis. Basel: Kruger, 1992;14:140–71.

Fielding CJ , Fielding PE. Molecular physiology of reverse cho-lesterol transport. J Lipid Res. 1995;36:211–28.

Li Z , McNamara JR , Ordovas JM , Schaefer EJ. Analysis if high density lipoproteins by a modified gradient gel electropheresis method. J Lipid Res. 1994;35:1698–1711.

Shumaker VN , Puppione DL. Sequential flotation ultracentrifu-gation. Methods Enzymol. 1986;128:155–70.

Puchois P , Kandoussi A , Feivet P , Fourier JL , Bertrand M , Koren E , Fruchart JC. Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis. 1991;68:35–41.

Genest J Jr , Bard JM , Fruchart JC , Ordovas JM , Wilson PWF , Schaefer EJ. Plasma apolipoproteins A-I, A-II, B, E, and CIII containing particles in men with premature coronary artery disease. Atherosclerosis. 1991;90:149–57.

Kawano M , Miida T , Fielding CJ , Fielding PE. Quantitation of Pre-b-HDL dependent and nonspecific components of the total efflux of cellular cholesterol and phospholipid. Biochem. 1993;32:5025–8.

Brinton EA , Eisenberg S , Breslow JL. Increased apoA-I and apoA-II fractional catabolic rate in patients with low high density lipoprotein cholesterol levels with or without hypertriglyceridemia. J Clin Invest. 1991;87:536–44.

Emmerich J , Verges B , Tauveron I , Rader D , Sammaritano-Fojo S , Schaefer J , Ayrault-Jarrier M , Thieblot P , Brewer B Jr . Familial HDL deficiency due to marked hypercatabolism of normal apo AΙ. Arterioscler Thromb Vasc Biol. 1993;13:1299–1306.

Horowitz BS , Goldberg IJ , Merab J , Vanni TM , Ramakrishnan R. Increased plasma and renal clearance of an exchangeable pool of apolipoproteins A-I in subjects with low levels of high density lipopro-tein cholesterol. J Clin Invest. 1993;91:1743–52.

Le AN , Ginsberg HN. Heterogeneity of apolipoprotein A-I turnover with reduced concentrations of plasma high density lipoprotein cholesterol. Metabolism. 1988;37:614–7.

Rader DJ , Gregg RE , Meng MS , Schaefer JR , Zech LA , Benson MD , Brewer HB Jr . In vivo metabolism of a mutant apolipoprotein apo AIIowa, associated with hypoalphalipoproteinemia and systemic amyloi-dosis. J Lipid Res. 1992;33:755–63.

Rader DJ , Ikewaki K , Duverger N , Feuerstein I , Zech L , Connor W , Brewer HB Jr . Very low high-density lipoproteins without coronary atherosclerosis. Lancet. 1993;342:8885.

Schaefer EJ , Ordovas JM. Metabolism of apolipoproteins A-I, A-II, and A-IV. Methods Enzymol. 1986;129:420–43.

Breslow JL. Lipoprotein transport abnormalities underlying heart disease susceptibility. Annu Rev Med. 1991;42:357–71.

Roma P , Gregg RE , Meng MS , Ronan R , Zech LA , Franceschini G , Sirtori CR , Brewer HB. In vivo metabolism of a mutant form of apolipoprotein A-I, apo A-IMilano, associated with hypoalphalipopro-teinemia. J Clin Invest. 1993;91:1445–52.

Johnson JJ , Chacko GK , Phillips MC , Rothblat GH. The efflux of lysosomal cholesterol from cells. J Biol Chem. 1990;265:5546–53.

De la Llera Moya M , Atger V , Paul JL , Fournier N , Moatti N , Giral P , Friday KE , Rothblat G. A cell culture system for screening human serum for ability to promote cellular cholesterol efflux. Relations between serum components and efflux, esterification, and transfer. Arterioscler Thromb Vasc Biol. 1994;14:1056–65.

Davidson WS , Gillotte KL , Lund-Kats S , Johnson WJ , Rothblat GH , Phillips MC. The effect of high density lipoprotein phospholipid acyl chain composition on the efflux of cellular cholesterol. J Biol Chem. 1995;270:5882.

McKnight GL , Reasoner J , Gilbert T , Sundquist KO , Hokland B , McKernan PA , Champagne J , Johnson CJ , Bailey MC , Holly R. Cloning and expression of a cellular HDL binding protein that is up-regulated by cholesterol loading of cells. J Biol Chem. 1992;267:12131–41.

Oram JF , Mendez AJ , Slotte JP , Johnson TF. High density lipoprotein apolipoproteins mediate removal of sterol from intracellular pools but not from plasma membranes of cholesterol-loaded fibroblasts. Arterioscler Thromb Vasc Biol. 1991;11:403–14.

Kruse C , Grunweller A , Notbom H , Kugler S , Purschke WG , Muller PK. Evidence for a novel cytoplasmic tRNA-protein complex containing the KH-multidomain protein vigilin. Biochem J. 1996;320:247–52.

Plenz G , Kugler S , Schnittger S , Rieder H , Fonatsch C , Muller PK. The human vigilin gene: identification, chromosomal localization and expression patterns. Hum Genet. 1994;93:575–82.

Mendez AJ , Oram JF , Bierman EL. Protein kinase C as a media-tor of high density lipoprotein receptor-dependent efflux of intracellular cholesterol. J Biol Chem. 1991;266:10104–11.

Deeg MA , Garver WS , Bierman EL , Oram JF. HDL stimulates phosphorylation of 18 and 80 kDa proteins in cholesterol-loaded human skin fibroblasts. Circulation. 1993;88:Abs 1215.

Drobnick W , Mollers C , Resink T , Schmitz G. Activation of phosphatidyl-specific phospholipase C in response to HDL3 and LDL is markedly reduced in cultured fibroblasts from Tangier patients. Aterioscler Thromb Vasc Biol. 1995;15:1369–77.

Walter M , Reinecke H , Gerdes U , Nofer J-R , Hobbel G , Seedorf U , Assman G. Defective regulation of phosphatidyl-choline-specific phospholipases C and D in a kindred with Tangier disease. J Clin Invest. 1996;98:2315–23.

Deeg MA , Bowen RF , Oram JF , Bierman EL. High density lipoproteins stimulate mitogen-activated protein kinases in human skin fibroblasts. Atheroscler Thromb Vasc Biol. 1997;17:1667–74.

Lange Y. Disposition of intracellular cholesterol in human fibroblasts. J Lipid Res. 1991;32:329–39.

Goldstein JL , Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343:425–30.

Lange Y , Matthies HJG . Transfer of cholesterol from its site of synthesis to the plasma membrane. J Biol Chem. 1984;259:14624–30.

Lange Y , Steck JL. Cholesterol-rich intracellular membranes: a precursor to the plasma membrane. J Biol Chem. 1985;260:15592–6.

Lange Y , Swaisgood MH , Ramos B , Steck TL. Plasma mem-branes contain half the phospholipid and 90% of the cholesterol and sphingomyelin in cultured human fibroblasts. J Biol Chem. 1989;264:3786–93.

Liscum L , Underwood KW. Intracellular cholesterol transport and compartmentation. J Biol Chem. 1995;270:15443–6.

Coxey RA , Pentchev PG , Campell G , Blanchette-Mackie EJ. Differential accumulation of cholesterol in Golgi compartments of nor-mal and Niemann-Pick type C fibroblasts incubated with LDL: a cyto-chemical freeze-fracture study. J Lipid Res. 1993;34:1165–76.

Mendez AJ. Monensin and Brefeldin A inhibit high density lipoprotein-mediated cholesterol efflux from cholesterol-enriched cells. J Biol Chem. 1995;270:5891–900.

Johnson WJ , Fisher RT , Philllips MC , Rothblat GH. Efflux of newly synthesized cholesterol and biosynthetic sterol intermediates from cells. J Biol Chem. 1995;270:25037–46.

Fielding PE , Fielding CJ. Plasma membrane caveolae mediate the efflux of cellular free cholesterol. Biochemistry. 1995;34:14288–92.

Smart EJ , Ying YS , Donzell WC , Anderson RG. A role for caveolin in transport of cholesterol from endoplasmic reticulum to plas-ma membrane. J Biol Chem. 1996;271:29427–35.

Lisanti MP , Tang Z , Scherer PE , Kubler E , Koleske AJ , Sargiacomo M. Caveolae, transmembrane signaling, and cellular trans-formation. Mol Membr Biol. 1995;12:121–4.

Walter M , Gerdes U , Seedorf U , Assmann G. The apolipoprotein AI-induced mobilization of cellular cholesterol is impaired in fibroblasts from Tangier disease subjects. Biochem Biopyhs Res Commun. 1994;205:850–6.

Rogler G , Trumbach B , Klima B , Lackner KJ , Schmitz G. HDL-mediated efflux of intracellular cholesterol is impared in fibroblasts from Tangier disease patients. Arterioscler Thromb Vasc Biol. 1995;15:683–690.

Francis GA , Knopp RH , Oram JF. Defective removal of cellular cholesterol and phospholipids by apolipoprotein Al in Tangier disease. J Clin Invest. 1995;96:78–87.

Hajjar DP , Haberland ME. Lipoprotein trafficking in vascular cells. Molecular Trojan horses and cellular saboteurs. J Biol Chem. 1997;272:22975–8.

Yoshikawa M , Sakuma N , Hibino T , Sato T , Fujinami T. HDL, exerts more powerful anti-oxidative, protective effects against copper-catalyzed LDL oxidation than HDL. Clin Biochem. 1997;30:221–5.

Banka CL. High density lipoprotein and lipoprotein oxidation. Curr Opin Lipidol. 1996;7:139–42.

Watson AD , Berliner JA , Hama SY , La Du BN , Faull KF , Fogelman AM , Navab M. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimal-ly oxidized low density lipoprotein. J Clin Invest. 1995;96:2882–91.

Raeven E , Tsai L , Azhar S. Cholesterol uptake by the selective pathway of ovarian granulosa cells: early intracellular events. J Lipid Res. 1995;36:1602–17.

Wurfel MM , Kunitake ST , Lichenstein H , Kane JP , Wright SD. Lipopoly-saccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med. 1994;180:1025–35.

Hager KM , Hajduk SL. Mechanism of resistance of African try-panosomes to cytotoxic human HDL. Nature. 1997;385:823–6.

Raper J , Nussenzweig V , Tomlinson S. The main lytic factor of Trypanosoma brucei brucei in normal human serum is not high density lipoprotein. J Exp Med. 1996;183:1023–9.

Yuan Y , Jackson SP , Newnham HH , Mitchell CA , Salem HH. An essential role for lysophosphatidylcholine in the inhibition of platelet aggregation by secretory phospholipase A2. Blood. 1995;86:4166–74.

Fujimoto Y , Tsunomori M , Muta E , Yamamoto T , Nishida H , Sakuma S , Fujita T. High density lipoprotein inhibits platelet 12-lipoxy-genase activity. Res Comm Mol Pathol Pharmacol. 1994;85:355–8.

Genest J Jr , Martin-Munley SS , McNamara JR , Ordovas JM , Jenner JL , Meyers RH , Silberman SR , Wilson PWF , Salem DN , Schaefer EJ. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation. 1992;85:2025–33.

Williams RR , Hunt SC , Hopkins PN , Stults BM , Wu LL , Hasstedt SJ , Barlow GK , Stephenson SH , Lalouel J-M , Kuida H. Familial dyslipidemic hypertension. Evidence from 58 Utah families for a syndrome present in approximately 12% of patients with essential hypertension. JAMA. 1988;259:3579–86.

Hopkins PN , Hunt SC , Wu LL , Williams GH , Williams RR. Hypertension, dyslipidemia and insulin resistance: links in a chain or spokes on a wheel. Curr Opin Lipidol. 1996;7:241–53.

Mahaney MC , Blangero J , Rainwater DL , Comuzzie AG , Van de Berg JL , Stern MP , MacCluer JW , Hixson JE. A major locus influencing plasma high-density lipoprotein cholesterol levels in the San Antonio Family Heart Study. Segregation and linkage analyses. Arterioscler Thromb Vasc Biol. 1995;15:1730–9.

Hegele RA , Brunt JH , Connelly PW. Multiple genetic determi-nants of variation of plasma lipoproteins in Alberta Hutterites. Arterioscler Thromb Vasc Biol. 1995;15:861–71.

Williams RR , Hunt SC , Hopkins PN , Wu LL , Hasstedt SJ , Berry TD , Barlow GK , Stults BM , Schumacher MC , Ludwig EH . Genetic basis of familial dyslipidemia and hypertenson: 15-year results from Utah. Am J Hypertens. 1993;6:319S–27S.

Heiba IM , De Meester CA , Xia YR , Diep A , George VT , Amos CI , Srinivasan SR , Berenson GS , Elston RC , Lusis AJ. Genetic contribu-tions to quantitative lipoprotein traits associated with coronary artery disease: analysis of a large pedigree from the Bogalusa Heart Study. Am J Med Genet. 1993;47:875–83.

Breslow JL. Familial disorders of high density lipoprotein metab-olism. In: Scriver CR , Beaudet AL , Sly WS and Valle D , eds. The meta-bolic and molecular basis of inherited disease, 7th edition. McGraw-Hill, USA. 1995;2031–52.

Ng NS , Leiter LA , Vezina C , Connelly PW , Hegele RA. Apolipoprotein A-I Q[-2]X causing isolated apolipoprotein AI deficien-cy in a family with analphalipoproteinemia. J Clin Invest. 1994;93:223–9.

Ordovas JM , Cassidy DK , Civeira F , Bisgaier CL , Schaefer EJ. Familial apolipoprotein A-I, C-III and A-IV deficiency and premature atherosclerosis due to deletion of a gene complex on chromosome 11. J Biol Chem. 1989;264:16339–42.

Takata K , Saku K , Ohta T , Takata M , Bai H , Jimi S , Liu R , Sato H , Kajiyama G , Arakawa K. A new case of apo Al deficiency showing codon 8 nonsense mutation of the apo AI gene without evidence of coro-nary artery disease. Atheroscler Thromb Vasc Biol. 1995;15:1866–74.

Moriyama K , Sasaki J , Takada Y , Matsanuga A , Fukui J , Albers JJ , Arakawa K. A cysteine containing truncated apo AI variant associated with HDL deficiency. Atheroscler Thromb Vasc Biol. 1996;16:1416–23.

Funke H , von Eckardstein A , Pritchard PH , Karas M , Albers JJ , Assmann G. A frameshift mutation in the human apolipoprotein A-I gene causes high density lipoprotein deficiency, partial lecithin:choles-terol-acyltransferase deficiency, and corneal opacities. J Clin Invest. 1991;87:371–6.

Romling R , von Eckardstein A , Funke H , Motti C , Fragiacomo GC , Noseda G , Assmann G. A nonsense mutation in the apolipoprotein A-I gene is associated with high-density lipoprotein deficiency and peri-orbital xanthelasmas. Arterioscler Thromb Vasc Biol. 1994;14:1915–22.

Deeb SS , Cheung MC , Peng R , Wolf AC , Stern R , Albrs JJ , Knopp RH. A mutation in the human apolipoprotein A-I gene. Dominant effect on the level and characteristics of plasma high density lipopro-teins. J Biol Chem. 1991;266:13654–60.

Miccoli R , Bertolotto A , Navalesi R , Odoguardi L , Boni A , Wessling J , Funke H , Wiebusch H , Eckardstein A , Assmann G. Compound heterozygosity for a structural apolipoprotein A-I variant, apo A-I(L141R)Pisa, and an apolipoprotein A-I null allele in patients with absence of HDL cholesterol, corneal opacifications, and coronary heart disease. Circulation. 1996;94:1622–8.

Funke H , von Eckardstein A , Pritchard PH , Hornby AE , Wiebusch H , Motti C , Hayden MR , Dachet C , Jacotot B , Gerdes U , Faegeman O , Albers JJ , Colleoni N , Catapano A , Frohlich J , Assmann G. Genetic and phenotypic heterogeneity in familial lecithin:cholesterol acyltransferase (LCAT) deficiency. J Clin Invest. 1993;91:677–83.

Kuivenhoven JA , Pritchard H , Hill J , Frohlich J , Assmann G , Kastelein J. The molecular pathology of lecithin: cholesterol acyltrans-ferase (LCAT) deficiency syndromes. J Lipid Res. 1997;38:191–205.

Serfaty-Lacrosniere C , Civiera F , Lanzberg A , Isaia P , Berg J , Janus ED , Smith MP Jr , Pritchard PH , Frohlich J , Lees RS. Homozygous Tangier disease and cardiovascular disease. Atherosclerosis. 1994;107:85–98.

Assmann G , von Eckardstein A , Brewer HB Jr . Familial high density lipoprotein deficiency: Tangier disease. In: Scriver CR , Beaudet AL , Sly WS , Valle D , eds. The metabolic and molecular basis of inherit-ed disease, 7th edition. McGraw-Hill, USA. 1995;2053–72.

Ma Y , Henderson HE , Murthy V , Roederer G , Monsalve MV , Clarke LA , Normand T , Julien P , Gagne C , Lambert M. A mutation in the human lipoprotein lipase gene as the most common cause of familial chylomicronemia in French Canadians. N Engl J Med. 1991;324:1761–6.

Ma Y , Wilson BI , Bijvoet S , Henderson HE , Cramb E , Roederer G , Ven Murthy MR , Julien P , Bakker HD , Kastelein JJ. A mis-sense mutation (Asp250->Asn) in exon 6 of the human lipoprotein lipase gene causes chylomicronemia in patients of different ancestries. Genomics. 1992;13:649–53.

Hegele RA , Tu L , McGuire GF , Connelly PW. Molecular basis and allele specific screening of Apo CII St Michaels. Clin Biochem. 1992;25:309–12.

Hirano K , Yamashita S , Nakajima N , Arai T , Maruyama T , Yoshida Y , Ishigami M , Sakai N , Kameda-Takemura K , Matsazuwa Y. Genetic cholesteryl ester transfer protein deficiency is extremely fre-quent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Atheroscler Thromb Vasc Biol. 1997;17:1053–9.

Calabresi L , Franceschini G. High density lipoprotein and coro-nary heart disease: insights from mutations leading to low high density lipoprotein. Curr Opin Lipidol. 1997;8:219–24.

Vigushin DM , Gough J , Allan D , Algaunal A , Penne B , Pettigrew NM. Familial nephropathy amyloidosis. QJM. 1994;87:149–54.

Soutar AK. Systemic amyloidosis Arg 26 apo AI. Proc Natl Acad Sci USA. 1992;89:7389–93.

Miccoli R , Zhu Y , Daum U , Wessling J , Huang Y , Navalesi R , Assmann G , von Eckardstein A. A natural apolipoprotein A-I variant, apoA-I(L141R)Pisa, interferes with the formation of a-high density lipoproteins (HDL) but not with the formation of preß,-HDL and influ-ences efflux of cholesterol into plasma. J Lipid Res. 1997;38:1242–53.

von Eckardstein A , Funke H , Henke A , Altland K , Benninghoven A , Assmann G. Apolipoprotein A-I variants. Naturally occurring substitutions of proline residues affect plasma concentration of apolipoprotein A-I. J Clin Invest. 1989;84:1722–30.

Carlson LA , Holmquist L. Evidence for deficiency of high den-sity lipoprotein lecithin:cholesterol acyltransferase activity (LCAT) in Fish-Eye disease. Acta Medica Scandivanvia. 1985;218:189–96.

Frohlich J , McLeod R , Pritchard PH , Fesmire J , McConathy W. Plasma lipoprotein abnormalities in heterozygous for lecithin:cholesterol-acyltransferase deficiency. Metabolism. 1988;37:3–8.

Remaley AT , Schumacher JA , Farsi JA , Nazih BD , Brewer HB Jr . Decreased reverse cholesterol transport from Tangier disease fibrob-lasts. Acceptor specificity and effects of brefeldin on lipid efflux. Atheroscler Thromb Vasc Biol. 1997;17:1813–21.

Marcil M , Boucher B , Frohlich J , Davignon J , Solymoss BC , Genest J Jr . Severe Familial HDL deficiency in French Canadian kin-dred: biochemical and molecular characterization. Arterioscler Thromb Vasc Biol. 1995;15:1015–24.

Batal R , Tremblay M , Krimbou L , Mamer O , Davignon J , Genest J Jr , Cohn JS. Familial deficiency characterized by hypercatabo-lism of mature apo AI but not proapoAI. Atheroscler Thromb Vasc Biol. 1998;18:655–66.

Marcil M , Lu Yu L , Boucher B , Oram J , Genest J Jr . Cellular cholesterol transport and efflux from fibroblasts is abnormal in subjects with familial HDL deficiency. Atheroscler Thromb Vasc Biol. 1999;19:159–69.

Cheung MC , Mendez AJ , Wolf AC , Knopp RH. Characterization of apolipoprotein A-I and A-II-containing lipoproteins in a new case of high density lipoprotein deficiency resembling Tangier disease and their effects on intracellular cholesterol entux. J Clin invest 1993; 19: 522–9.

Carstea ED , Morris JA , Coleman KG , Loftus SK, Zhang D , Cummings C , Gu J , Rosenfeld MA, Pavan WJ , Krizman DB, Nagle J , Polymeropoulos MH, Sturley SL , loannu YA, Higgins ME , Comly M , Cooney A , Brown A , Kaneski CR , Blanchette-Mackie EJ, Dwyer NK , Neufeld EB, Chang TY , Liscum L , Table DA. Neimann-Pick C1 disease gene; homology to mediators of cholesterol homeostasis. Science 1997;277:228-31.

Huang Y, von Eckardstein A , Wu S , Maeda N , Assman G. A plasma lipoprotein containing only apolipoprotein E and with γ mobility on electropheresis releases cholesterol from cells. Proc Natl Acad Sci USA 1994;91:1834–8.

Krimbou L, Tremblay M , Davignon J , Cohn J. Characterization of human plasma apolipoprotein E-containing lipoproteins in the HDL size range: focus on pre- β₁-LpE, pre- β₂LpE and α-LpE. J Lipid Res 1997;38:35–48.

von Eckardstein A, Huang Y , Wu S , Funke H , Noseda G , Assmann G. Reverse cholesterol transport in plasma of patients with different forms of familial HDL deficiency. Arterioscler Thromb Vasc Biol 1995;15:691–703.

Schaefer EJ , Levy RI. Pathogenesis and management of lipoprotein disorders. N Eng J Med 1985;312:1300–10.